3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Vomiting
1
Substance-Related Disorders
1
Solid Tumors
1
Recurrence
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Opioid-Related Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma
1
Low Anterior Resection Syndrome
1
Colonic Neoplasms
1
Acromegaly
1
Interventions
Docetaxel
158
Prednisone
131
Leuprolide
95
bicalutamide
86
enzalutamide
83
Radiotherapy
80
Goserelin
80
Abiraterone Acetate
76
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
54
Magnetic Resonance Spectroscopy
46
Zoledronic Acid
44
gallium 68 PSMA-11
37
Flutamide
34
abiraterone
32
Estramustine
32
radium Ra 223 dichloride
30
apalutamide
27
Surveys and Questionnaires
26
Gonadotropin-Releasing Hormone
26
Androgen Antagonists
25
cabazitaxel
24
Radiosurgery
24
Dutasteride
22
sipuleucel-T
21
Prednisolone
21
Triptorelin Pamoate
20
Paclitaxel
20
luprolide acetate gel depot
19
Radiation
19
Exercise
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Prostatic Neoplasms
×
Dosage Forms
×
Clear all
NCT00913068
2021-10-04
TAP
Nova Scotia Health Authority
Phase NA
Completed
110 enrolled
5 charts
NCT01784757
2021-03-17
ARAFOR
Orion Corporation, Orion Pharma
Phase 1
Completed
30 enrolled